Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chugai Pharmaceutical Co., Ltd. announced that FDA has accepted the complete response resubmission that Roche made to the U.S. Food and Drug Administration for the Biologics License Application for Actemra the humanized anti–human IL–6 receptor monoclonal antibody, following the receipt of the Complete Response Letter in September 2008.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address